Pharmacokinetics of tofacitinib, a janus kinase inhibitor, in patients with impaired renal function and end-stage renal disease

Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve-month data from a twenty-four-month phase III randomized radiographic study

(2013) Désirée van der Heijde et al.   ARTHRITIS AND RHEUMATISM

Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial

(2013) Gerd R Burmester et al.   LANCET

Randomized Phase 2b Trial of Tofacitinib (CP-690,550) in De Novo Kidney Transplant Patients: Efficacy, Renal Function and Safety at 1 Year

(2012) F. Vincenti et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study

(2012) K.A. Papp et al.   BRITISH JOURNAL OF DERMATOLOGY

Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis

(2012) Roy Fleischmann et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis

(2012) Ronald F. van Vollenhoven et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis

(2012) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis

(2010) Debra M Meyer et al.   Journal of Inflammation-London

Membrane transporters in drug development

(2010)   NATURE REVIEWS DRUG DISCOVERY

Drug Development Perspective on Pharmacokinetic Studies of New Drugs in Patients With Renal Impairment

(2009) R L Lalonde et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

The Influence of Chronic Renal Failure on Drug Metabolism and Transport

(2009) A W Dreisbach   CLINICAL PHARMACOLOGY & THERAPEUTICS

Effect of CP-690,550, an Orally Active Janus Kinase Inhibitor, on Renal Function in Healthy Adult Volunteers

(2009) Nervin Lawendy et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Altered nonrenal drug clearance in ESRD

(2008) Thomas D Nolin   CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION